NeuroSense Therapeutics Ltd. Statistics
Share Statistics
NeuroSense Therapeutics Ltd. has 49.60M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 49.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -1.06 and the forward PE ratio is null.
| PE Ratio | -1.06 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -5.71 |
| P/FCF Ratio | -1.26 |
| PEG Ratio | n/a |
Enterprise Valuation
NeuroSense Therapeutics Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of 0.
| Current Ratio | 0.84 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -21.91 |
Financial Efficiency
Return on equity (ROE) is 5.39% and return on capital (ROIC) is 695.67%.
| Return on Equity (ROE) | 5.39% |
| Return on Assets (ROA) | -3.18% |
| Return on Capital (ROIC) | 695.67% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -561.50K |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.56, so NeuroSense Therapeutics Ltd.'s price volatility has been higher than the market average.
| Beta | 1.56 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.2 |
| Relative Strength Index (RSI) | 58.43 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, NeuroSense Therapeutics Ltd. had revenue of $0 and earned -$10.11M in profits. Earnings per share was $-0.83.
| Revenue | 0 |
| Gross Profit | -97.00K |
| Operating Income | -12.05M |
| Net Income | -10.11M |
| EBITDA | -10.63M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.83 |
Balance Sheet
The company has $2.64M in cash and $142.00K in debt, giving a net cash position of $2.50M.
| Cash & Cash Equivalents | 2.64M |
| Total Debt | 142.00K |
| Net Cash | 2.50M |
| Retained Earnings | -32.07M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -$8.45M and capital expenditures -$29.00K, giving a free cash flow of -$8.48M.
| Operating Cash Flow | -8.45M |
| Capital Expenditures | -29.00K |
| Free Cash Flow | -8.48M |
| FCF Per Share | -0.62 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NRSNW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for NRSNW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |